Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

A Successful Steroid-Sparing Approach in Cronkhite-Canada Syndrome.

Mao EJ, Hyder SM, DeNucci TD, Fine S.

ACG Case Rep J. 2019 Mar 27;6(3):1-4. doi: 10.14309/crj.0000000000000055. eCollection 2019 Mar.

2.

APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice.

Liang Y, Besch-Williford C, Cook MT, Belenchia A, Brekken RA, Hyder SM.

Breast Cancer (Dove Med Press). 2019 Jul 31;11:249-259. doi: 10.2147/BCTT.S208706. eCollection 2019.

3.

Complications Associated with Permanent Internal Jugular Hemodialysis Catheter: A Retrospective Study.

Hyder SMS, Iqbal J, Lutfi IA, Shazlee MK, Hamid K, Rashid S.

Cureus. 2019 Apr 22;11(4):e4521. doi: 10.7759/cureus.4521.

4.

A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts.

Liang Y, Mafuvadze B, Besch-Williford C, Hyder SM.

Breast Cancer (Dove Med Press). 2018 Mar 22;10:53-67. doi: 10.2147/BCTT.S156285. eCollection 2018.

5.
6.

Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro.

Goyette S, Liang Y, Mafuvadze B, Cook MT, Munir M, Hyder SM.

Breast Cancer (Dove Med Press). 2017 May 19;9:347-357. doi: 10.2147/BCTT.S135371. eCollection 2017.

7.

Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells.

Cook MT, Liang Y, Besch-Williford C, Hyder SM.

Breast Cancer (Dove Med Press). 2016 Dec 23;9:9-19. doi: 10.2147/BCTT.S124860. eCollection 2017.

8.

Initial experience with a novel EUS-guided core biopsy needle (SharkCore): results of a large North American multicenter study.

DiMaio CJ, Kolb JM, Benias PC, Shah H, Shah S, Haluszka O, Maranki J, Sharzehi K, Lam E, Gordon SR, Hyder SM, Kaimakliotis PZ, Allaparthi SB, Gress FG, Sethi A, Shah AR, Nieto J, Kaul V, Kothari S, Kothari TH, Ho S, Izzy MJ, Sharma NR, Watson RR, Muthusamy VR, Pleskow DK, Berzin TM, Sawhney M, Aljahdi E, Ryou M, Wong CK, Gupta P, Yang D, Gonzalez S, Adler DG.

Endosc Int Open. 2016 Sep;4(9):E974-9. doi: 10.1055/s-0042-112581. Epub 2016 Aug 30.

9.

Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells.

Liang Y, Mafuvadze B, Aebi JD, Hyder SM.

Onco Targets Ther. 2016 May 30;9:3223-32. doi: 10.2147/OTT.S105725. eCollection 2016.

10.

Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients.

Levenick JM, Gordon SR, Fadden LL, Levy LC, Rockacy MJ, Hyder SM, Lacy BE, Bensen SP, Parr DD, Gardner TB.

Gastroenterology. 2016 Apr;150(4):911-7; quiz e19. doi: 10.1053/j.gastro.2015.12.040. Epub 2016 Jan 9.

11.

Luteolin suppresses development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats.

Cook MT, Mafuvadze B, Besch-Williford C, Ellersieck MR, Goyette S, Hyder SM.

Oncol Rep. 2016 Feb;35(2):825-32. doi: 10.3892/or.2015.4431. Epub 2015 Nov 17.

PMID:
26719029
12.

Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts.

Cook MT, Liang Y, Besch-Williford C, Goyette S, Mafuvadze B, Hyder SM.

Springerplus. 2015 Aug 22;4:444. doi: 10.1186/s40064-015-1242-x. eCollection 2015.

13.

Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor.

Mafuvadze B, Liang Y, Hyder SM.

Oncol Rep. 2014 Oct;32(4):1727-33. doi: 10.3892/or.2014.3332. Epub 2014 Jul 15.

PMID:
25051231
14.

Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071.

Liang Y, Besch-Williford C, Aebi JD, Mafuvadze B, Cook MT, Zou X, Hyder SM.

Breast Cancer Res Treat. 2014 Jul;146(1):51-62. doi: 10.1007/s10549-014-2996-5. Epub 2014 May 31.

PMID:
24878988
15.

Effects of dietary apigenin on tumor latency, incidence and multiplicity in a medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced breast cancer model.

Mafuvadze B, Cook M, Xu Z, Besch-Williford CL, Hyder SM.

Nutr Cancer. 2013;65(8):1184-91. doi: 10.1080/01635581.2013.833637. Epub 2013 Oct 15.

PMID:
24127693
16.

Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy.

Neubauer H, Ruan X, Schneck H, Seeger H, Cahill MA, Liang Y, Mafuvadze B, Hyder SM, Fehm T, Mueck AO.

Menopause. 2013 May;20(5):504-10. doi: 10.1097/GME.0b013e3182755c97.

PMID:
23615641
17.

The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development.

Carroll CE, Liang Y, Benakanakere I, Besch-Williford C, Hyder SM.

Int J Oncol. 2013 Jan;42(1):179-87. doi: 10.3892/ijo.2012.1675. Epub 2012 Oct 24.

18.
19.

Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors.

Mafuvadze B, Liang Y, Besch-Williford C, Zhang X, Hyder SM.

Horm Cancer. 2012 Aug;3(4):160-71. doi: 10.1007/s12672-012-0114-x. Epub 2012 May 9.

PMID:
22569706
20.

Differential expression of FGF family members in a progestin-dependent BT-474 human breast cancer xenograft model.

López Pérez FR, Liang Y, Besch-Williford CL, Mafuvadze B, Hyder SM.

Histol Histopathol. 2012 Mar;27(3):337-45. doi: 10.14670/HH-27.337.

PMID:
22237711
21.

The mitochondrial protein C1qbp promotes cell proliferation, migration and resistance to cell death.

McGee AM, Douglas DL, Liang Y, Hyder SM, Baines CP.

Cell Cycle. 2011 Dec 1;10(23):4119-27. doi: 10.4161/cc.10.23.18287. Epub 2011 Dec 1.

22.

Apigenin prevents development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats.

Mafuvadze B, Benakanakere I, López Pérez FR, Besch-Williford C, Ellersieck MR, Hyder SM.

Cancer Prev Res (Phila). 2011 Aug;4(8):1316-24. doi: 10.1158/1940-6207.CAPR-10-0382. Epub 2011 Apr 19.

23.

An inverse docking approach for identifying new potential anti-cancer targets.

Grinter SZ, Liang Y, Huang SY, Hyder SM, Zou X.

J Mol Graph Model. 2011 Apr;29(6):795-9. doi: 10.1016/j.jmgm.2011.01.002. Epub 2011 Jan 19.

24.

Daily use of Sprinkles micronutrient powder for 2 months reduces anemia among children 6 to 36 months of age in the Kyrgyz Republic: a cluster-randomized trial.

Lundeen E, Schueth T, Toktobaev N, Zlotkin S, Hyder SM, Houser R.

Food Nutr Bull. 2010 Sep;31(3):446-60.

PMID:
20973465
25.

Synthetic progestins differentially promote or prevent 7,12-dimethylbenz(a)anthracene-induced mammary tumors in sprague-dawley rats.

Benakanakere I, Besch-Williford C, Carroll CE, Hyder SM.

Cancer Prev Res (Phila). 2010 Sep;3(9):1157-67. doi: 10.1158/1940-6207.CAPR-10-0064. Epub 2010 Aug 10.

26.

Apigenin blocks induction of vascular endothelial growth factor mRNA and protein in progestin-treated human breast cancer cells.

Mafuvadze B, Benakanakere I, Hyder SM.

Menopause. 2010 Sep-Oct;17(5):1055-63. doi: 10.1097/gme.0b013e3181dd052f.

PMID:
20551847
27.

Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice.

Liang Y, Benakanakere I, Besch-Williford C, Hyder RS, Ellersieck MR, Hyder SM.

Menopause. 2010 Sep-Oct;17(5):1040-7. doi: 10.1097/gme.0b013e3181d3dd0c.

28.

Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.

Liang Y, Besch-Williford C, Benakanakere I, Thorpe PE, Hyder SM.

Breast Cancer Res Treat. 2011 Jan;125(2):407-20. doi: 10.1007/s10549-010-0851-x. Epub 2010 Mar 27.

29.

PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.

Liang Y, Besch-Williford C, Hyder SM.

Int J Oncol. 2009 Nov;35(5):1015-23.

PMID:
19787255
30.

Curcumin delays development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors.

Carroll CE, Benakanakere I, Besch-Williford C, Ellersieck MR, Hyder SM.

Menopause. 2010 Jan-Feb;17(1):178-84. doi: 10.1097/gme.0b013e3181afcce5.

31.

Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells.

Hyder SM, Liang Y, Wu J, Welbern V.

Endocr Relat Cancer. 2009 Sep;16(3):809-17. doi: 10.1677/ERC-08-0311. Epub 2009 Jul 1.

PMID:
19570906
32.

Unexpectedly high early prevalence of anaemia in 6-month-old breast-fed infants in rural Bangladesh.

Shakur YA, Choudhury N, Hyder SM, Zlotkin SH.

Public Health Nutr. 2010 Jan;13(1):4-11. doi: 10.1017/S1368980009005886. Epub 2009 May 28.

PMID:
19476679
33.

Estrogen regulation of thrombospondin-1 in human breast cancer cells.

Hyder SM, Liang Y, Wu J.

Int J Cancer. 2009 Sep 1;125(5):1045-53. doi: 10.1002/ijc.24373.

34.

Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study.

Benakanakere I, Besch-Williford C, Ellersieck MR, Hyder SM.

Endocr Relat Cancer. 2009 Mar;16(1):85-98. doi: 10.1677/ERC-08-0069. Epub 2008 Dec 15.

PMID:
19075036
35.

Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells.

Carroll CE, Ellersieck MR, Hyder SM.

Menopause. 2008 May-Jun;15(3):570-4. doi: 10.1097/gme.0b013e31814fae5d.

PMID:
18467956
36.

Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics.

Liang Y, Besch-Williford C, Brekken RA, Hyder SM.

Cancer Res. 2007 Oct 15;67(20):9929-36.

37.

Improved adherence and anaemia cure rates with flexible administration of micronutrient Sprinkles: a new public health approach to anaemia control.

Ip H, Hyder SM, Haseen F, Rahman M, Zlotkin SH.

Eur J Clin Nutr. 2009 Feb;63(2):165-72. Epub 2007 Sep 26.

PMID:
17895911
38.

Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells.

Liang Y, Besch-Williford C, Benakanakere I, Hyder SM.

Int J Oncol. 2007 Oct;31(4):777-84.

PMID:
17786308
39.

A multiple-micronutrient-fortified beverage affects hemoglobin, iron, and vitamin A status and growth in adolescent girls in rural Bangladesh.

Hyder SM, Haseen F, Khan M, Schaetzel T, Jalal CS, Rahman M, Lönnerdal B, Mannar V, Mehansho H.

J Nutr. 2007 Sep;137(9):2147-53.

PMID:
17709456
40.
41.
42.

Sex-steroid regulation of vascular endothelial growth factor in breast cancer.

Hyder SM.

Endocr Relat Cancer. 2006 Sep;13(3):667-87. Review.

PMID:
16954424
43.

Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats.

Benakanakere I, Besch-Williford C, Schnell J, Brandt S, Ellersieck MR, Molinolo A, Hyder SM.

Clin Cancer Res. 2006 Jul 1;12(13):4062-71.

44.

Identification and characterization of two novel splicing isoforms of human estrogen-related receptor beta.

Zhou W, Liu Z, Wu J, Liu JH, Hyder SM, Antoniou E, Lubahn DB.

J Clin Endocrinol Metab. 2006 Feb;91(2):569-79. Epub 2005 Dec 6.

PMID:
16332939
46.

p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.

Liang Y, Wu J, Stancel GM, Hyder SM.

J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):173-82. Epub 2005 Jan 28.

PMID:
15860260
48.

Micronutrient sprinkles to control childhood anaemia.

Zlotkin SH, Schauer C, Christofides A, Sharieff W, Tondeur MC, Hyder SM.

PLoS Med. 2005 Jan;2(1):e1. No abstract available.

49.

Controlling iron deficiency anemia through the use of home-fortified complementary foods.

Zlotkin SH, Christofides AL, Hyder SM, Schauer CS, Tondeur MC, Sharieff W.

Indian J Pediatr. 2004 Nov;71(11):1015-9. Review.

PMID:
15572823
50.

Anaemia and iron deficiency during pregnancy in rural Bangladesh.

Hyder SM, Persson LA, Chowdhury M, Lönnerdal BO, Ekström EC.

Public Health Nutr. 2004 Dec;7(8):1065-70.

Supplemental Content

Loading ...
Support Center